+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Peptide Oligonucleotide Conjugate Market - Global Forecast 2025-2030- Product Image
Peptide Oligonucleotide Conjugate Market - Global Forecast 2025-2030- Product Image
Sale

Peptide Oligonucleotide Conjugate Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6126930
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Peptide oligonucleotide conjugates are transforming the approach to targeted drug delivery, seamlessly combining the specificity of oligonucleotides with the advanced delivery functions of engineered peptides. As a rapidly developing field, these novel therapeutics are drawing significant attention from senior leadership across the biopharmaceutical landscape for their potential to resolve longstanding barriers in clinical delivery and therapeutic efficacy.

Market Snapshot: Peptide Oligonucleotide Conjugate Landscape

The global peptide oligonucleotide conjugate market is in a dynamic phase of growth, driven by technological innovation, regulation, and evolving clinical strategies. Stakeholders are observing intensifying research output and accelerated translation from preclinical studies to clinical pipelines. High-throughput technologies in peptide optimization and advances in conjugation chemistry continue to set new standards for design precision and delivery performance. Cross-sector partnerships and refined regulatory frameworks are shaping a landscape where targeted therapies for genetic, infectious, neurological, and oncological applications are approaching greater clinical and commercial viability.

Scope & Segmentation

This report delivers in-depth coverage across key sectors, segments, and regions driving the adoption of peptide oligonucleotide conjugates.

  • Conjugation Types: Cell penetrating conjugates (including amphipathic, arginine rich, and cationic), and receptor targeting conjugates (utilizing ligands for folate, integrin, and transferrin receptors).
  • Therapeutic Areas: Indications spanning genetic disorders, infectious diseases (bacterial, parasitic, viral), neurological disorders (Alzheimer’s, ALS, Parkinson’s), and oncology (hematological and solid tumors).
  • Administration Routes: Intravenous (bolus, infusion), subcutaneous (auto and manual injection), and topical (cream, patch) options tailored to optimize bioavailability and patient compliance.
  • End Users: Biopharmaceutical companies (biotech SMEs and large pharma), academic and community hospitals, public and private research institutes, and specialist clinics focused on neurology or oncology.
  • Regional Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (notably UK, Germany, France, and other key markets), Asia-Pacific (China, India, Japan, Australia, South Korea, and Southeast Asia).
  • Leading Companies: Organizations with strong footprints in the field include Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, QIAGEN N.V., Bachem Holding AG, GenScript Biotech Corporation, LGC Limited, Bio-Synthesis, Inc., Panagene Inc., and Peptide Synthetics Ltd.

Key Takeaways for Senior Decision-Makers

  • Hybrid peptide oligonucleotide conjugates are removing bottlenecks associated with bioavailability, off-target effects, and controlled intracellular delivery, reinforcing opportunities for differentiated drug pipelines.
  • Technological evolution, such as modular linker chemistries and advanced computational modeling, is enabling iterative, data-driven product design for faster lead optimization.
  • Receptor targeting and cell-penetrating strategies are being tailored by indication, which supports tissue specificity and minimizes systemic side effects in clinical settings.
  • Regulators are refining guidance and requirements for oligonucleotide-based therapeutics, which is clarifying pathways toward approval and shaping corporate risk management.
  • Cross-functional collaborations between academic institutions, biotech innovators, and large pharma are accelerating pipeline advancement and mitigating technical and regulatory hurdles.

Tariff Impact: Navigating the 2025 U.S. Trade Environment

New United States tariffs on imported peptide and oligonucleotide precursors are impacting supply chain models, leading organizations to reassess procurement strategies and ramp up domestic production capacity. This shift requires notable operational adaptation, increased capital investment, and strategic collaborations to manage material sourcing and mitigate cost escalations. Regional partnerships and flexible procurement frameworks are proving essential to ensure continued innovation and project momentum in light of these trade dynamics.

Methodology & Data Sources

This analytic report integrates qualitative and quantitative approaches, including reviews of peer-reviewed literature, patent analyses, and proprietary databases. Structured expert interviews provide context and validation, while segmentation analysis and regional mapping offer granular visibility into emerging trends and corporate strategies.

Why This Report Matters

  • Strategic insights support informed decisions regarding investment, R&D prioritization, and entry into high-value market segments within the peptide oligonucleotide conjugate sector.
  • Clear breakdowns of segmentation, technology advances, and regional trends enable effective risk management and alignment with evolving regulatory landscapes.
  • Operational recommendations equip stakeholders with actionable strategies for development, supply chain resilience, and cross-sector collaboration.

Conclusion

By addressing technological, clinical, and regulatory complexities, this report provides clarity and strategic foresight for executive leaders. Forward-looking organizations will be best positioned to capitalize on emerging opportunities as peptide oligonucleotide conjugates advance toward broader therapeutic adoption.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing investment in targeted delivery systems for peptide oligonucleotide conjugates in rare diseases
5.2. Integration of cell-penetrating peptides to enhance intracellular delivery efficiency of oligonucleotide therapeutics
5.3. Advancements in linker chemistry optimizing stability and release profiles of peptide-oligonucleotide conjugates
5.4. Regulatory frameworks adaptation for novel peptide oligonucleotide conjugate therapies across major markets
5.5. Emerging manufacturing scale-up strategies to reduce production costs of peptide oligonucleotide conjugates
5.6. Collaborations between biotech and pharma aimed at accelerating clinical trials of peptide oligonucleotide conjugates
5.7. Adoption of AI-driven design platforms to predict peptide-oligonucleotide conjugate efficacy and safety in preclinical studies
5.8. Patent landscape evolution concerning peptide oligonucleotide conjugate inventions and exclusivity trends
5.9. Commercialization pathways exploring partnerships for peptide oligonucleotide conjugate pipeline assets in oncology
5.10. Impact of personalized medicine initiatives on the demand for customized peptide oligonucleotide conjugate treatments
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Peptide Oligonucleotide Conjugate Market, by Conjugation Type
8.1. Introduction
8.2. Cell Penetrating
8.2.1. Amphipathic
8.2.2. Arginine Rich
8.2.3. Cationic
8.3. Receptor Targeting
8.3.1. Folate Receptor
8.3.2. Integrin Receptor
8.3.3. Transferrin Receptor
9. Peptide Oligonucleotide Conjugate Market, by Therapeutic Area
9.1. Introduction
9.2. Genetic Disorders
9.2.1. Duchenne Muscular Dystrophy
9.2.2. Spinal Muscular Atrophy
9.3. Infectious Diseases
9.3.1. Bacterial
9.3.2. Parasitic
9.3.3. Viral
9.4. Neurological Disorders
9.4.1. Alzheimer’s Disease
9.4.2. Amyotrophic Lateral Sclerosis
9.4.3. Parkinson’s Disease
9.5. Oncology
9.5.1. Hematological Malignancies
9.5.2. Solid Tumors
10. Peptide Oligonucleotide Conjugate Market, by Route of Administration
10.1. Introduction
10.2. Intravenous
10.2.1. Bolus Injection
10.2.2. Infusion
10.3. Subcutaneous
10.3.1. Auto Injection
10.3.2. Manual Injection
10.4. Topical
10.4.1. Cream
10.4.2. Patch
11. Peptide Oligonucleotide Conjugate Market, by End User
11.1. Introduction
11.2. Biopharmaceutical Companies
11.2.1. Biotech Smes
11.2.2. Large Pharma
11.3. Hospitals
11.3.1. Academic Hospitals
11.3.2. Community Hospitals
11.4. Research Institutes
11.4.1. Private Labs
11.4.2. Public Research Institutes
11.5. Specialist Clinics
11.5.1. Neurology Clinics
11.5.2. Oncology Clinics
12. Americas Peptide Oligonucleotide Conjugate Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Peptide Oligonucleotide Conjugate Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Peptide Oligonucleotide Conjugate Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific Inc.
15.3.2. Merck KGaA
15.3.3. Danaher Corporation
15.3.4. QIAGEN N.V.
15.3.5. Bachem Holding AG
15.3.6. GenScript Biotech Corporation
15.3.7. LGC Limited
15.3.8. Bio-Synthesis, Inc.
15.3.9. Panagene Inc.
15.3.10. Peptide Synthetics Ltd.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET: RESEARCHAI
FIGURE 24. PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET: RESEARCHSTATISTICS
FIGURE 25. PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET: RESEARCHCONTACTS
FIGURE 26. PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMPHIPATHIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMPHIPATHIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ARGININE RICH, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ARGININE RICH, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CATIONIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CATIONIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY FOLATE RECEPTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY FOLATE RECEPTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTEGRIN RECEPTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTEGRIN RECEPTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TRANSFERRIN RECEPTOR, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TRANSFERRIN RECEPTOR, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY DUCHENNE MUSCULAR DYSTROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPINAL MUSCULAR ATROPHY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BACTERIAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARASITIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARASITIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY VIRAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY VIRAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ALZHEIMER’S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AMYOTROPHIC LATERAL SCLEROSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PARKINSON’S DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HEMATOLOGICAL MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BOLUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AUTO INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY AUTO INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY MANUAL INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY MANUAL INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CREAM, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PATCH, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PATCH, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOTECH SMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOTECH SMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY LARGE PHARMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PRIVATE LABS, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY PUBLIC RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 129. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2024 (USD MILLION)
TABLE 130. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2025-2030 (USD MILLION)
TABLE 131. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2024 (USD MILLION)
TABLE 132. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2025-2030 (USD MILLION)
TABLE 133. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2024 (USD MILLION)
TABLE 134. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2025-2030 (USD MILLION)
TABLE 135. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 136. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 137. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 138. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 139. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 140. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 141. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 142. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 143. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 144. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 165. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2024 (USD MILLION)
TABLE 168. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2025-2030 (USD MILLION)
TABLE 169. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2024 (USD MILLION)
TABLE 170. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2025-2030 (USD MILLION)
TABLE 171. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 172. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 173. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 174. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 175. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 176. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 177. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 178. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 179. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 180. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 181. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 182. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 201. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2024 (USD MILLION)
TABLE 202. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2025-2030 (USD MILLION)
TABLE 203. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2024 (USD MILLION)
TABLE 204. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2025-2030 (USD MILLION)
TABLE 205. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2024 (USD MILLION)
TABLE 206. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2025-2030 (USD MILLION)
TABLE 207. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 208. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 209. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 210. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 211. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 212. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 213. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 214. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 215. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 216. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 217. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 220. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 221. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 222. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 223. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 224. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 225. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 228. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 229. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 230. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 231. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 232. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 233. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 234. CANADA PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 235. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2024 (USD MILLION)
TABLE 236. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2025-2030 (USD MILLION)
TABLE 237. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2024 (USD MILLION)
TABLE 238. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2025-2030 (USD MILLION)
TABLE 239. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2024 (USD MILLION)
TABLE 240. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2025-2030 (USD MILLION)
TABLE 241. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 242. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 243. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 244. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 245. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 246. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 247. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 248. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 249. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 250. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 251. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 254. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 255. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 256. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 257. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 258. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 259. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2018-2024 (USD MILLION)
TABLE 262. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, 2025-2030 (USD MILLION)
TABLE 263. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
TABLE 264. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY HOSPITALS, 2025-2030 (USD MILLION)
TABLE 265. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
TABLE 266. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2030 (USD MILLION)
TABLE 267. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2018-2024 (USD MILLION)
TABLE 268. MEXICO PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SPECIALIST CLINICS, 2025-2030 (USD MILLION)
TABLE 269. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2018-2024 (USD MILLION)
TABLE 270. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CONJUGATION TYPE, 2025-2030 (USD MILLION)
TABLE 271. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2018-2024 (USD MILLION)
TABLE 272. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY CELL PENETRATING, 2025-2030 (USD MILLION)
TABLE 273. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2018-2024 (USD MILLION)
TABLE 274. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY RECEPTOR TARGETING, 2025-2030 (USD MILLION)
TABLE 275. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
TABLE 276. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY THERAPEUTIC AREA, 2025-2030 (USD MILLION)
TABLE 277. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2018-2024 (USD MILLION)
TABLE 278. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY GENETIC DISORDERS, 2025-2030 (USD MILLION)
TABLE 279. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 280. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 281. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2024 (USD MILLION)
TABLE 282. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2025-2030 (USD MILLION)
TABLE 283. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 284. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 285. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2018-2024 (USD MILLION)
TABLE 288. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY INTRAVENOUS, 2025-2030 (USD MILLION)
TABLE 289. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2018-2024 (USD MILLION)
TABLE 290. BRAZIL PEPTIDE OLIGONUCLEOTIDE CONJUGATE MARKET SIZE, BY SUBCUTANEOUS, 2025-2030 (USD MILLION)
TABLE 291. BRAZIL PEPT

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Peptide Oligonucleotide Conjugate market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • QIAGEN N.V.
  • Bachem Holding AG
  • GenScript Biotech Corporation
  • LGC Limited
  • Bio-Synthesis, Inc.
  • Panagene Inc.
  • Peptide Synthetics Ltd.

Related Reports

Antibody-oligonucleotide Conjugates Market - Global Forecast 2025-2030 - Product Image

Antibody-oligonucleotide Conjugates Market - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
Oligonucleotide Conjugates Market - Global Forecast 2025-2030 - Product Image

Oligonucleotide Conjugates Market - Global Forecast 2025-2030

  • Report
  • 186 Pages
  • Global
From
Next Generation Drug Conjugates Market Report 2025 - Product Image

Next Generation Drug Conjugates Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Next Generation Drug Conjugates Market Industry Trends and Global Forecast to 2035, by Type of Next Generation Drug Conjugates, Type of Targeting Ligand, Type of Payload, Type of Therapy, Route of Administration, Key Target Indications and Key Geographical Regions - Product Image

Next Generation Drug Conjugates Market Industry Trends and Global Forecast to 2035, by Type of Next Generation Drug Conjugates, Type of Targeting Ligand, Type of Payload, Type of Therapy, Route of Administration, Key Target Indications and Key Geographical Regions

  • Report
  • 120 Pages
  • Global
From
Bioconjugation Market by Product (Consumables, Instruments (Chromatography, Spectrometry)), Service (Conjugation, Analytical), Technique (Chemical, Click Chemistry), Biomolecule (Antibodies), Application (Therapeutics (ADC), R&D) - Global Forecast to 2029 - Product Image

Bioconjugation Market by Product (Consumables, Instruments (Chromatography, Spectrometry)), Service (Conjugation, Analytical), Technique (Chemical, Click Chemistry), Biomolecule (Antibodies), Application (Therapeutics (ADC), R&D) - Global Forecast to 2029

  • Report
  • 683 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.